J Korean Soc Transplant.  2011 Jun;25(2):76-80.

Treatment of Recurrent Nephrotic Syndrome after Transplantation

• Kang HG
• Ha IS

Abstract

Focal segmental glomerulosclerosis (FSGS) is the most common glomerulopathy that progresses to end-stage renal disease in children. It is also notorious for frequent recurrence after transplantation. The recurrence of FSGS after transplant leads to the loss of the grafts in nearly half of the recurrent cases, especially in those who did not respond to treatment. Remission can be achieved in majority of the recurrent patients as long as the treatment is initiated early enough (<48 hours after onset). Since recurrence typically manifests as massive proteinuria, usually within a few days after the engraftment, close monitoring of proteinuria and prompt treatment on recurrence is advisable. Plasmapheresis to remove the 'circulating factor' been used as a mainstay of treatment of the recurrence; on each session, one to two times of plasma volume is exchanged, and the treatment is continued for 8~12 sessions or until remission is achieved. High dose cyclosporine is another arm of commonly practiced treatment with good result. Recently, depletion of B cells by rituximab has been tried as another option of treatment of recurrence, with excellent response by some and no response by others. Again, prompt administration of the treatment seems critical to achieve remission. The efficacy of pre-emptive, prophylactic plasmapheresis before transplantation is controversial. In summary, the recurrence of primary FSGS is observed in more than half of the children after transplantation. Prompt initiation of treatment would improve the survival. To improve the prognosis of recurrent primary nephrotic syndrome/FSGS, close monitoring and multidisciplinary approach is required.

Keyword

Nephrotic syndrome; Recurrence; Treatment outcome; Child; Focal segmental glomerulosclerosis; Plasmapheresis

MeSH Terms

Antibodies, Monoclonal, Murine-Derived
Arm
B-Lymphocytes
Child
Cyclosporine
Glomerulosclerosis, Focal Segmental
Humans
Kidney Failure, Chronic
Nephrotic Syndrome
Plasma Volume
Plasmapheresis
Prognosis
Proteinuria
Recurrence
Rituximab
Transplants
Treatment Outcome
Antibodies, Monoclonal, Murine-Derived
Cyclosporine
Glomerulosclerosis, Focal Segmental

Reference

References

1). Baum MA, Stablein DM, Panzarino VM, Tejani A, Harmon WE, Alexander SR. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int. 2001; 59:328–33.

2). Stewart JH, McCredie MR, McDonald SP. The incidence of treated end-stage renal disease in New Zealand Maori and Pacific Island people and in Indigenous Australians. Nephrol Dial Transplant. 2004; 19:678–85.

3). Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996; 334:878–83.

4). Pradhan M, Petro J, Palmer J, Meyers K, Baluarte HJ. Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol. 2003; 18:934–8.

5). Kim SJ, Ha J, Jung IM, Ahn MS, Kim M, Lee HS, et al. Recurrent focal segmental glomerulosclerosis following renal transplantation in Korean pediatric patients. Pediatr Transplant. 2001; 5:105–11.

6). Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant. 2010; 14:314–25.

7). Hubsch H, Montané B, Abitbol C, Chandar J, Shariatmadar S, Ciancio G, et al. Recurrent focal glomerulosclerosis in pediatric renal allografts: the Miami experience. Pediatr Nephrol. 2005; 20:210–6.

8). Hoyer JR, Vernier RL, Najarian JS, Raij L, Simmons RL, Michael AF. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet. 1972; 2:343–8.

9). Baum MA. Outcomes after renal transplantation for FSGS in children. Pediatr Transplant. 2004; 8:329–33.

10). Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation. 2009; 87:1232–9.

11). Ingulli E, Tejani A. Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children–a singlecenter experience. Transplantation. 1991; 51:401–5.

12). McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010; 5:2115–21.

13). Freiberger V, Amann K, Heemann U, Frank H. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transpl Int. 2009; 22:1110–3.

14). Hamasaki Y, Yoshikawa N, Hattori S, Sasaki S, Iijima K, Nakanishi K, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009; 24:2177–85.

15). Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008; 14:931–8.

16). Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol. 2010; 25:1197–9.

17). Banfi G, Colturi C, Montagnino G, Ponticelli C. The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine. Transplantation. 1990; 50:594–6.

18). Schwarz A, Krause PH, Offermann G, Keller F. Recurrent and de novo renal disease after kidney transplantation with or without cyclosporine A. Am J Kidney Dis. 1991; 17:524–31.

19). Raafat RH, Kalia A, Travis LB, Diven SC. High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis. 2004; 44:50–6.

20). Salomon R, Gagnadoux MF, Niaudet P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation. 2003; 75:810–4.

21). Canaud G, Zuber J, Sberro R, Royale V, Anglicheau D, Snanoudj R, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant. 2009; 9:1081–6.

22). van Husen M, Kemper MJ. New therapies in ste-roid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2011; 26:881–92.

23). Roberti I, Vyas S. Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol. 2010; 25:1117–24.

24). Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol. 2005; 20:1660–3.

25). Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int. 2007; 20:102–5.

26). Gossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser IA. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int. 2007; 20:558–62.

27). Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int. 2007; 20:1066–71.

28). Bayrakci US, Baskin E, Sakalli H, Karakayali H, Haberal M. Rituximab for post-transplant recurrences of FSGS. Pediatr Transplant. 2009; 13:240–3.

29). Dello Strologo L, Guzzo I, Laurenzi C, Vivarelli M, Parodi A, Barbano G, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation. 2009; 88:417–20.

30). Apeland T, Hartmann A. Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation. Nephrol Dial Transplant. 2008; 23:2091–4.

31). Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006; 354:1961–3.

32). Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010; 126:e243–6.

33). Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol. 2009; 44:922–34.

34). Couloures K, Pepkowitz SH, Goldfinger D, Kamil ES, Puliyanda DP. Preventing recurrence of focal segmental glomerulosclerosis following renal transplantation: a case report. Pediatr Transplant. 2006; 10:962–5.

35). Gohh RY, Yango AF, Morrissey PE, Monaco AP, Gautam A, Sharma M, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant. 2005; 5:2907–12.

36). Mahesh S, Del Rio M, Feuerstein D, Greenstein S, Schechner R, Tellis V, et al. Demographics and response to therapeutic plasma exchange in pediatric renal transplantation for focal glomerulosclerosis: a single center experience. Pediatr Transplant. 2008; 12:682–8.

37). Ohta T, Kawaguchi H, Hattori M, Komatsu Y, Akioka Y, Nagata M, et al. Effect of pre-and postoperative plasmapheresis on posttransplant recurrence of focal segmental glomerulosclerosis in children. Transplantation. 2001; 71:628–33.

38). Valdivia P, Gonzalez Roncero F, Gentil MA, Jimenez F, Algarra G, Pereira P, et al. Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant. Transplant Proc. 2005; 37:1473–4.

39). KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9(Suppl 3):S1–155.